Drug Trial Radar · NCT06849713
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
May 16, 2025
Primary completion
Mar 1, 2028
Study completion Mar 1, 2030
Sponsor
- Lead sponsor
- Massachusetts General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- BeOne Medicines
- First posted
- Feb 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma (SLL)
Interventions
ZanubrutinibDrug
Bruton's Tyrosine Kinase (BTK) inhibitor
SonrotoclaxDrug
B-cell lymphoma 2 (BCL2) protein inhibitor
ObinutuzumabDrug
Anti-CD20 monoclonal antibody
TacabrutidegDrug
Bruton's Tyrosine Kinase (BTK) degrader
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Undetectable MRD (uMRD) at Best ResponseTime frame: Day 1 to 2 years after final patient enrolled
- Proportion of Participants with Tumor Lysis Syndrome (TLS) Laboratory Abnormalities Requiring InterventionTime frame: Day 1 to completion date of sonrotoclax ramp-up
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.